Citations

Showing 10 of 108119 citations.

Paradoxical increase in ambulatory systolic blood pressure in coarctation of aorta as compared to idiopathic hypertension
Iftikhar, M , Devara, Janaki , Shaik, Likhita, Katta, Renuka Reddy, Goda, Akiko , Egbe, A, Connolly, Heidi M. , Egbe, Alexander C.

Mayo Clinic

European Heart Journal | October 21, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.1859 Get It

Abstract Background The relationship between office vs ambulatory blood pressure (BP) indices is well-studied in patients with idiopathic hypertension, and based on these data, it is known that average 24-hour ambulatory BP is typically lower than office BP. However, emerging data show that office systolic BP (SBP) underestimates arterial afterload in patients with coarctation of aorta (COA), and minimal increase in stroke volume during low intensity exercise results in exaggerated rise in SBP as compared to those with idiopathic hypertension. We hypothesized that COA patients will have higher ambulatory SBP and a higher prevalence of masked hypertension compared to patients with idiopathic hypertension. Methods Case-control study of 118 COA patients and 118 patients with idiopathic hypertension matched by age, sex, body mass index and office SBP. Results Although both groups had similar office SBP (132±17 mmHg) by design, the COA group had paradoxical increases in 24-hour ambulatory SBP (135±14 vs 126±13, p<0.001) and daytime ambulatory SBP (142±16 vs 130±13, p<0.001), and less nocturnal dipping (−3±5 vs −9±4, p<0.001). The COA group also had a higher prevalence of masked hypertension (36 [31%] vs 14 [12%], p<0.001), and worse arterial function indices. Conclusion These findings underscore the potential limitations of relying on office SBP for screening/monitoring of hypertension in COA and potential pitfalls in extrapolating idiopathic hypertension guidelines recommendations to the treatment of COA. It also provides rationale for further studies to determine if pharmacologic BP interventions guided by ambulatory BP data will improve clinical outcomes in the COA population. Funding Acknowledgement Type of funding sources: None.
Outcomes of transctheter mitral valve repair in a large urban US health system
Hahn, Joshua , Virk, Hafeez Hassan, Greason, K, Al-Azza, F, Krittanawong, Chayakrit

Mayo Clinic

European Heart Journal | October 21, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.1632 Get It

Abstract Background Transcatheter mitral valve repair (TMVR) has become an important minimally invasive alternative to open surgical repair in patients with severe mitral regurgitation. As TMVR develops as an established practice, real-world outcome data is needed to guide clinical decision making as the body of literature on this topic is limited. In our study, we investigate TMVR outcomes in a large urban health system. Methods We retrospectively analyzed clinical data from the electronic health records of the extensive urban health system Mount Sinai Data Warehouse and analyzed all individuals who underwent TMVR. Baseline demographics were obtained as well as significant morbidity and mortality outcomes. Finally, multivariable analysis was used to determine associated characteristics with mortality. Results We identified 3533 patients who underwent TMVR from 2008 to 2018. The overall mortality was 3.7%. The most common comorbidities observed were heart failure (56%), pulmonary hypertension (26%), atrial fibrillation (26%) and CKD or ESRD (16%). After multivariable analyses, ischemic stroke (adjusted OR 3.46; 95% CI 1.93–5.97, p = <0.001), CKD or ESRD (3.95; 2.72–5.75, p 0.01), aortic stenosis (2.23; 1.12–4.15, p<0.001), and heart failure (8.18; 4.16–18.5, p<0.001) were independently associated with mortality. Conclusion In all patients who underwent TMVR at a large urban health system, ischemic stroke, aortic stenosis, heart failure, CKD and ESRD were independently associated with mortality. Future prospective studies will be needed to further define these observed associations. Funding Acknowledgement Type of funding sources: None.
Prognostic implications of left heart diastolic dysfunction in adults with coarctation of aorta
Katta, Renuka Reddy, Goda, Akiko , Devara, Janaki , Iftikhar, M , Shaik, Likhita, Egbe, Alexander C. , Connolly, Heidi M.

Mayo Clinic

European Heart Journal | October 21, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.1873 Get It

Abstract Background Left atrial dysfunction (LAD) and left ventricular diastolic dysfunction (LVDD) has been described in patients with coarctation of aorta (COA). However, it is unknown whether LA function and LV diastolic function indices can be used for prognostication in this population. The purpose of this study was to determine whether LAD and LVDD were associated with mortality in adults with COA. We hypothesized that LA and LV diastolic function indices will predict transplant-free survival in COA patients. Methods Retrospective study of COA patients (age ≥18) at Mayo Clinic (2000–2018). LVDD was determined using the 2016 guidelines for LVDD assessment, and LAD was assessed using LA reservoir strain. Results Of 721 patients, LV diastolic function could be determined in 635 (88%), while 86 (12%) were classified as indeterminate diastolic function. Of 635 patients, 414 (65%) had no LVDD, while 146 (23%), 53 (8%), and 22 (4%) had grade I/II/III LVDD respectively. The mean LA reservoir strain was −39±11%, and patients were divided into quartiles: top quartile (reference group), mild LAD, moderate LAD, and severe LAD. Of 635 patients, 49 died and 4 underwent heart transplant. On multivariate analysis, Grade III diastolic dysfunction (but not Grade I and II) was associated with mortality as compared to normal diastolic function. On the other hand, there was an incremental risk of mortality across LA strain quartiles: mild LAD (HR 1.16, 1.04–2.06), moderate LAD (HR 1.75, 1.27–3.58), and severe LAD (HR 3.49, 1.88–7.16). Of the 86 patients with indeterminate diastolic function, LAD was associated with a lower 5-year transplant-free survival as compared to normal LA function (83% vs 91%, p=0.06). Conclusions LAD (but not LVDD) was associated with incremental risk of mortality, and thus can be used for prognostication in all patients including those with indeterminate diastolic function. Although the current study did not identify a consistent relationship between LVDD severity classifications and mortality among COA patients, it does not imply that LVDD is benign. Rather it suggests that the conventional criteria for LVDD severity classifications may not be generalizable to every disease subgroup Funding Acknowledgement Type of funding sources: None.
Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium
Sharda, Nidhi, Curran, Geoffry L., Lowe, Val J. , Kandimalla, Karunya K. , Wang, Zengtao , Kandimalla, Karunya K , Wang, Zengtao , Li, Ling

Mayo Clinic

Molecular Pharmaceutics | October 20, 2021 | Volume: 18 | Issue: 11 | Pages: 4148-4161

10.1021/acs.molpharmaceut.1c00549 | PMID 34664956 Get It

Corrigendum to ‘Induction of Wnt signaling antagonists and p21-activated kinase enhances cardiomyocyte proliferation during zebrafish heart regeneration’
Peng, Xiangwen , Lai, Kaa Seng, She, Peilu , Wang, Tingting , Zhou, Yating , Sun, Jianjian , Jin, Da‐Qing , Liao, Lujian , Liu, Jiandong , Zhong, Tao P. , Kang, Junsu , Li, Guobao, Jin, Daqing, Xu, Xiaolei , Lee, Ethan N. , Poss, Kenneth D.

Mayo Clinic

Journal of Molecular Cell Biology | October 20, 2021 | Volume: 13 | Issue: 12 | Pages: 921-921

10.1093/jmcb/mjab064 | PMID 35092682 Get It

Diagnostic Methods and Risk Factors for Severe Disease and Mortality in Blastomycosis: A Retrospective Cohort Study
O’Dowd, Timothy R., Hugh, Jack W. Mc, Theel, Elitza S. , Wengenack, Nancy L. , Enzler, Mark J., Vergidis, Paschalis , McHugh, Jack , Mc Hugh, Jack W, Vergidis, Paschalis , McHugh, Jack , O’Horo, John C.

Mayo Clinic

Journal of Fungi | October 20, 2021 | Volume: 7 | Issue: 11 | Pages: 888

10.3390/jof7110888 | PMID 34829177 Get It

Background: Blastomycosis can cause severe disease with progressive respiratory failure and dissemination even in immunocompetent individuals. We sought to evaluate risk factors for severe disease and mortality using clinical and laboratory data within a large health system in an endemic area. Methods: We performed a retrospective cohort study of patients diagnosed with blastomycosis at all Mayo Clinic sites from 1 January 2004 through 31 March 2020. Diagnosis was established by culture, histopathology/cytopathology, serology, antigen testing, or PCR. Disease was categorized as mild for patients treated in the outpatient setting, moderate for hospitalized patients who did not require intensive care, and severe for patients admitted to the intensive care unit. Logistic regression was used to evaluate risk factors for severe disease. A Cox proportional hazards model was constructed to evaluate mortality. Findings: We identified 210 patients diagnosed with blastomycosis. Mean age was 51 years (range, 6–84). Most subjects were male (71.0%). Extrapulmonary disease was confirmed in 24.8%. In this cohort, 40.5% of patients had mild disease, 37.6% had moderate disease, and 21.9% had severe disease. Independent risk factors for severe disease were neutrophilia (odds ratio (OR) 3.35 (95% CI 1.53–7.35), p = 0.002) and lymphopenia (OR 3.34 (95% CI 1.59–7.03), p = 0.001). Mortality at 90 days was 11.9%. Median time from diagnosis to death was 23 days (interquartile range 8–31 days). Independent risk factors for mortality were age (OR 1.04 (95% CI 1.01–1.08), p = 0.009), neutrophilia (OR 2.84 (95% CI 1.04–7.76), p = 0.041), and lymphopenia (OR 4.50 (95% CI 1.67–12.11), p = 0.003). Blastomyces immunodiffusion had an overall sensitivity of 39.6% (95% CI 30.1–49.8). Sensitivity was higher among those who were tested 4 weeks or longer after the onset of symptoms. Urine Blastomyces antigen had a significantly higher sensitivity of 80.8% (95% CI 68.1–89.2) compared to serology. There was a trend towards higher antigen concentration in patients with severe disease. The sensitivity of PCR from respiratory specimens was 67.6% (95% CI 50.1–85.5). Conclusion: In this cohort, we did not find an association between pharmacologic immunosuppression and disease severity. Lymphopenia at diagnosis was an independent risk factor for mortality. This simple marker may aid clinicians in determining disease prognosis.
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Castellino, Alessia , Wang, Yucai , Maurer, Matthew J. , Link, Brian K. , Farooq, Umar , Feldman, Andrew L. , Syrbu, Sergei , Inwards, David J. , Ansell, Stephen M. , Allmer, Cristine, Cohen, Jonathon B. , Martin, Peter , Nowakowski, Grzegorz S. , Maurer, Matthew , Link, Brian K , Feldman, Andrew L , Paludo, Jonas , Witzig, T.E. , Cohen, Jonathon B , Cerhan, James R , Farooq, Umar , Wang, Yucai , Syrbu, Sergei , Larson, Melissa C. , Habermann, Thomas M. , Paludo, Jonas , Witzig, Thomas E. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Blood Advances | October 20, 2021 | Volume: 6 | Issue: 4 | Pages: 1350-1360

10.1182/bloodadvances.2021005715 | PMID 34662895 Get It

AbstractBecause there have been a dvances in frontline treatment for mantle cell lymphoma (MCL) over the last 2 decades, we sought to characterize the changes in frontline treatment patterns and their association with outcomes. Patients with newly diagnosed MCL from September 2002 through June 2015 were enrolled in a prospective cohort study, and clinical characteristics, treatment, and clinical outcomes were compared between patients diagnosed from 2002 to 2009 (Era 1) compared with 2010 to 2015 (Era 2). Patient age, sex, and simplified MCL International Prognostic Index (sMIPI) score were similar between the 2 groups. In patients age 65 years or younger, there was less use of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R-Hyper-CVAD) (16.1% vs 8.8%) but more use of rituximab plus maximum-strength cyclophosphamide, doxorubicin, vincristine, and prednisone (R-maxi-CHOP) alternating with rituximab plus high-dose cytarabine (R-HiDAC), also known as the Nordic regimen, and R-CHOP alternating with rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) (1.1% vs 26.4%) and less use of R-CHOP or R-CHOP-like regimens (64.5% vs 35.2%) but more use of R-bendamustine (0% vs 12.1%) in Era 2 (P < .001). These changes were associated with improved event-free survival (EFS; 5-year EFS, 34.3% vs 50.0%; P = .010) and overall survival (OS; 5-year OS, 68.8% vs 81.6%; P = .017) in Era 2. In patients older than age 65 years, there was less use of R-CHOP or R-CHOP-like therapy (39.0% vs 14.3%) and nonstandard systemic therapy (36.6% vs 13.0%) but more use of R-bendamustine (0% vs 49.4%). These changes were associated with a trend for improved EFS (5-year EFS, 25.4% vs 37.5%; P = .051) in Era 2. The shift from R-CHOP or R-CHOP-like regimens to R-bendamustine was associated with improved EFS (5-year EFS, 25.0% vs 44.6%; P = .008) in Era 2. Results from this prospective cohort study provide critical real-world evidence for improved outcomes with evolving frontline patterns of care in patients with MCL.
Sex differences in cardio-oncology: utilizing a genetic variant as a therapeutic target doxorubicin-induced cardiomyopathy
Morales-Lara, Andrea Carolina , Diflorio, D N, Anastasiadis, Zacharias P., Landolfo, Carolyn, Ray, Jordan , Bruno, Katelyn A. , Norton, Nadine , Fairweather, DeLisa

Mayo Clinic

European Heart Journal | October 20, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.3263 Get It

Abstract Introduction Doxorubicin is an anthracycline used as a chemotherapeutic drug for the treatment of a wide range of adult and pediatric cancers. Doxorubicin is associated with an increased risk of cardiomyopathy and heart failure with up to 10% of patients developing cardiac complications. A GWAS conducted of 1,191 patients from the N9831 clinical trial identified that cardiac gene expression and genetic variants of TRPC6 were associated with a decline in left ventricular ejection fraction (LVEF) (p=0.005 and p=1.6x10–6, respectively). TRPC6 is a non-selective cation channel expressed in heart and vascular tissue. TRPC6 participates in the pathogenesis of cardiac hypertrophy as a pathological response to chronic mechanical stress. Chronic activation has been found to promote cardiac fibrosis leading to heart failure. Purpose TRPC6 variants could be associated with increased risk of doxorubicin-induced cardiotoxicity. Data/tests to determine which patients may progress to cardiomyopathy and heart failure are currently lacking and there are no targeted treatments to prevent cardiomyopathy in these patients. Methods In preliminary in vivo data, B6.129 wild-type mice or TRPC6 knockout mice were treated with either 6x intraperitoneal saline or 4mg/kg doxorubicin injections (cumulative dose of 24mg/kg). Results We found doxorubicin increased cardiac vacuolation (male, p≤0.001 and female, p≤0.05) in WT mice compared to controls. Higher HW/BW ratio was observed in male TRPC6 knock out mice compared to wild-type mice when both were treated with doxorubicin (males, p=0.005 and females, p=0.19). Additionally, we found that doxorubicin-induced cardiac injury was significantly reduced in TRPC6 knock-out mice compared to wild-type mice based on reduced vacuolation (p=0.0004 males, p=0.03 females), with the effect being greater in male mice than female mice. Furthermore, a significant decrease in stroke volume (p=0.007), diastolic volume (p=0.01) and cardiac output (p=0.004) in wild-type male mice treated with doxorubicin compared to control and TRPC6 knock-out mice. Our in vitro preliminary data show that inhibition of TRPC6 using the TRPC6 inhibitor GsMTx-4 in human iPSC-derived cardiomyocytes significantly reduced doxorubicin-induced apoptosis (p<0.0001). Further we treated male mice with the TRPC6 inhibitor, GsMTx4, and found that they had less global longitudinal cardiac strain (p=0.04) and higher ejection fraction (p=0.01) compared to mice who were only treated with doxorubicin. Histologically we found that mice given the TRPC6 inhibitor had less fibrosis as measured by Trichrome stained heart sections (p=0.004) which could account for improvements in cardiac function. Conclusion TRPC6 could be a novel therapeutic target in the prevention of chemotherapy-induced cardiomyopathy and heart failure. Additionally genetic mapping of TRCP6 functional variants may provide a new screening tool to determine increased risk of developing heart failure. Funding Acknowledgement Type of funding sources: Private hospital(s). Main funding source(s): Mayo Clinic
Catheter ablation of ventricular tachycardia in patients with postinfarction left ventricular aneurysm
Amin, Mustapha, Hilaire, Emilie, Siontis, Konstantinos C. , Madhavan, Malini , Mulpuru, Siva K. , Deshmukh, Abhishek , Cha, Yong‐Mei , Friedman, Paul A. , Munger, Thomas M. , Asirvatham, Samuel J. , Killu, Ammar M. , Farwati, Medhat , Siontis, Konstantinos C , Madhavan, Malini , Kapa, Suraj , Mulpuru, Siva K , Deshmukh, Abhishek J , Cha, Yong-Mei , Friedman, Paul A , Munger, Thomas, Asirvatham, Samuel J , Killu, Ammar M , Kapa, Suraj

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 20, 2021 | Volume: 32 | Issue: 12 | Pages: 3156-3164

10.1111/jce.15273 | PMID 34664765 Get It

AbstractBackgroundWhile ventricular tachycardia (VT) in the setting of postmyocardial infarction left ventricular aneurysms (LVA) is not uncommonly encountered, there is a scarcity of data regarding the safety, efficacy, and outcomes of ablation of VT in this subset of patients.MethodsOur study included consecutive patients aged 18 years or older with postmyocardial infarction LVA who presented to Mayo Clinic for catheter ablation of VT between 2002 and 2018.ResultsOf 34 patients, the mean age was 70.4 ± 9.1 years; 91% were male. Mean LVEF was 29 ± 9.7% and left ventricular end‐diastolic dimension was 64.9 ± 6.6 mm. The site of the LVA was apical in 21 patients (62%). Fifteen patients (44%) presented with electrical storm or incessant VT. Nine patients (26%) had a history of intracardiac thrombus. All except for one patient had at least one VT originating from the aneurysm. The mean number of VTs was 2.9 ± 1.7. All patients underwent ablation at the site of the aneurysm. Ablation outside the aneurysm was performed in 13 patients (38%). Low‐voltage fractionated potentials and/or late potentials at the aneurysmal site were present in all cases. Complete elimination of all VTs was achieved in 18 (53%), while the elimination of the clinical VT with continued inducibility of nonclinical VTs was achieved in a further 11 patients (32%). Two patients developed cardiac tamponade requiring pericardiocentesis. During a mean follow‐up period of 2.3 ± 2.4 years, 11 patients (32%) experienced VT recurrence. Freedom from all‐cause mortality at 1‐year follow‐up was 94%.ConclusionRadiofrequency catheter ablation targeting the aneurysmal site is a feasible and reasonably effective management strategy for clinical VTs in patients with postinfarction LVA.
Acute Effects of Virtual Reality Exercise Biking on College Students’ Physical Responses
Zeng, Nan , Pope, Zachary , McDonough, Daniel J. , Gao, Zan , Pope, Zachary C, McDonough, Daniel J , Liu, Wenxi

Mayo Clinic

Research Quarterly for Exercise and Sport | October 20, 2021 | Volume: 93 | Issue: 3 | Pages: 633-639

10.1080/02701367.2021.1891188 | PMID 34663191 Get It